Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

By G. Scagliotti, F. Marinis, M. Rinaldi, L. Crinò, C. Gridelli, S. Ricci, E. Matano, C. Boni, M. Marangolo, G. Failla and 7 more. Journal of Clinical Oncology, 2002

899 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/5c973ada7e3328600c77553dbc6ad3b1b0b69667

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. C. Zappa
2. Shaker A. Mousa

Citations in the corpus

• Non-small cell lung cancer: current treatment and future advances. (2016, background): “Median overall survival for patients in these studies was approximately 8–10 months (35-38).”
• Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. (2006, neutral): “5 months reported in the literature [15, 16].”